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Abstract
Background: Progranulin is a secreted high molecular weight growth factor bearing seven and
one half copies of the cysteine-rich granulin-epithelin motif. While inappropriate over-expression
of the progranulin gene has been associated with many cancers, haploinsufficiency leads to atrophy
of the frontotemporal lobes and development of a form of dementia (frontotemporal lobar
degeneration with ubiquitin positive inclusions, FTLD-U) associated with the formation of
ubiquitinated inclusions. Recent reports indicate that progranulin has neurotrophic effects, which,
if confirmed would make progranulin the only neuroprotective growth factor that has been
associated genetically with a neurological disease in humans. Preliminary studies indicated high
progranulin gene expression in spinal cord motor neurons. However, it is uncertain what the role
of Progranulin is in normal or diseased motor neuron function. We have investigated progranulin
gene expression and subcellular localization in cultured mouse embryonic motor neurons and
examined the effect of progranulin over-expression and knockdown in the NSC-34 immortalized
motor neuron cell line upon proliferation and survival.
Results: In situ hybridisation and immunohistochemical techniques revealed that the progranulin
gene is highly expressed by motor neurons within the mouse spinal cord and in primary cultures
of dissociated mouse embryonic spinal cord-dorsal root ganglia. Confocal microscopy coupled to
immunocytochemistry together with the use of a progranulin-green fluorescent protein fusion
construct revealed progranulin to be located within compartments of the secretory pathway
including the Golgi apparatus. Stable transfection of the human progranulin gene into the NSC-34
motor neuron cell line stimulates the appearance of dendritic structures and provides sufficient
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trophic stimulus to survive serum deprivation for long periods (up to two months). This is mediated
at least in part through an anti-apoptotic mechanism. Control cells, while expressing basal levels of
progranulin do not survive in serum free conditions. Knockdown of progranulin expression using
shRNA technology further reduced cell survival.
Conclusion: Neurons are among the most long-lived cells in the body and are subject to low levels
of toxic challenges throughout life. We have demonstrated that progranulin is abundantly
expressed in motor neurons and is cytoprotective over prolonged periods when over-expressed
in a neuronal cell line. This work highlights the importance of progranulin as neuroprotective
growth factor and may represent a therapeutic target for neurodegenerative diseases including
motor neuron disease.
Background
The granulin-epithelin precursor, progranulin (PGRN)
[1], also called proepithelin [2], PC-cell-derived growth
factor [3], or acrogranin [4], is a secreted glycoprotein that
promotes mitosis, survival, and migration in many cell
types [5,6]. Recent work demonstrates that haploinsuffi-
ciency of the PGRN gene causes a form of frontotemporal
lobar degeneration (FTLD) that is associated with the for-
mation of ubiquitinated inclusions (FTLD-U) [7-9]. Sev-
eral studies have shown that ubiquitinated Tar-DNA
Binding Protein 43 (TDP-43) is a component of inclusion
bodies in both FTLD-U and Amyotrophic Lateral Sclerosis
(ALS) [10-13] although other ubiquitinated proteins are
also present in these inclusion bodies in ALS [14]. TDP-43
translocates from the nucleus to the cytoplasm in axot-
omized motor neurons which is consistent with a role for
TDP43 in the normal response of motor neurons to injury
[15]. The depletion of PGRN in H4 gliomas results in the
activation of caspase-3 and the accumulation of cleaved
TDP-43 [16]. This is suggestive of a functional relation-
ship between the loss of PGRN and mobilization of TDP-
43, although this conclusion has been challenged by other
investigators [17,18]. While PGRN is secreted by many
cell types it has been suggested that in neurons its subcel-
lular distribution resembles that of mitochondria or lyso-
somal-endosomal markers [19].
PGRN is synthesised in neurons in many brain regions
including the cerebral cortex, in the Purkinje cells of the
cerebellum, and in the hippocampus [20]. In addition, it
is widely distributed in the developing central nervous
system and the dorsal root and sympathetic ganglia
within the peripheral nervous system [21]. The roles of
PGRN in normal neuronal function and development, in
either the central or peripheral nervous systems are poorly
understood. It is known, however, that PGRN contributes
to normal brain development since it regulates the male-
specific differentiation of the neonatal hypothalamus
[22,23]. Moreover, in culture, PGRN stimulates the prolif-
eration of PC12 cells [20], as well as the estrogen-depend-
ent growth of hippocampal neurospheres [24] and may
be neurotrophic for cortical and motor neurons [25].
The signalling pathways associated with PGRN in neurons
are unknown, but in non-neuronal cell types it activates
growth factor-related signal transduction pathways
including the phosphorylation of shc, p44/42 mitogen-
activated protein kinase, phosphatidylinositol 3-kinase,
protein kinase B/AKT, and the p70S6 kinase [26-28], and,
by so doing, contributes to carcinogenesis in numerous
tumour types [29-39]. PGRN is involved in wound repair
and inflammation [40-43], and plays an important role in
early embryonic development [44-46]. The ability of
PGRN to regulate critical proliferative, survival and motil-
ity signals in a diverse range of non-neuronal cell types
suggests that it may support similar functions in nerve
cells.
In situ hybridization experiments (see below) revealed
that motor neurons express a high level of PGRN, suggest-
ing a significant role for PGRN in the biology of the motor
neuron. The significance of PGRN in healthy and diseased
motor neurons is, however, unclear. PGRN expression
was markedly up-regulated in spinal cord tissue from
patients who had ALS [47]. While this was probably due
to gliosis [47], increased immunoreactive staining for
PGRN has been reported both in motor neurons and glial
cells in spinal cord and brainstem tissue sections derived
from ALS patients relative to controls [48]. Furthermore,
PGRN expression is increased in the lumbar cord motor
neurons from murine models of familial ALS that is
caused by mutations in superoxide dismutase 1 (SOD1)
[49,50]. PGRN was one of only 21 genes with dysregu-
lated motor neuron expression in SOD1G37R  and
SOD1G85R mice at the onset of the disease, as judged by
weight loss but before the detection of overt neurological
symptoms [49]. The PGRN gene was also up-regulated in
SODG93A mice, but late in the disease progression [50]. In
contrast, a decrease in PGRN expression was noted in the
NSC-34 neuronal cell line engineered to express SODG93A
[51]. It has been suggested that the PGRN gene may be a
modulator of disease progression in ALS since a correla-
tion between genetic variations in PGRN and the age of
onset or survival of patients with ALS has been reported
[52]. This observation was not, however, reproduced byBMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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other investigators [53-55]. In some patients FTLD may be
accompanied by motor neuron disease [56,57], but muta-
tions in PGRN are infrequent in patients with ALS-FTLD
defects [54,58-60], and for those that have been reported
it is uncertain whether or not they are pathogenic [53,61].
Growth factors, in particular vascular endothelial growth
factor [62] and insulin-like growth factor-1 [63], have
shown promise as neuroprotective agents in murine mod-
els of familial ALS and if PGRN is neurotrophic for motor
neurons [25] it could also have therapeutic potential in
ALS. Given the uncertainty of whether or not PGRN con-
tributes to motor neuron function and survival, we sought
first to characterize the expression of PGRN in the healthy
brain, spinal cord and dorsal root ganglia, and then to
investigate its possible biological activities in an immor-
talized motor neuron cell model.
Results
PGRN is expressed within multiple neuronal cell 
populations of the mouse brain and spinal cord
The expression pattern of PGRN has been described in the
adult brain [21], but not in the remainder of the nervous
system. We investigated the expression of PGRN mRNA
and protein in normal mouse brain and spinal cord. In
situ hybridization (ISH) was performed on para-saggital
sections of brain, trans-sections of cervical spinal cord,
and primary cultures of dissociated spinal cord-dorsal
root ganglia (DRGs) (Figure 1). PGRN mRNA was
detected within numerous neural cell types within the
grey matter of the spinal cord (Figure 1A). Motor neurons
in brain (pontine grey matter, Figure 1B) and ventral horn
of the cervical cord (Figure 1D) (identification based on a
distinctive cell body size (>20 um) [64]) robustly
expressed PGRN mRNA. Motor neurons were routinely
the first cell population to become visible during chrom-
agen development of the ISH signal. The expression of
PGRN mRNA was investigated in primary cultures of
murine spinal cord-DRG. PGRN was expressed within
motor neurons, as well as other neuronal cells (Figure 1F).
Expression of PGRN at the protein level was demonstrated
by the presence of PGRN-immunoreactive protein within
motor neurons in cross-sections of the lumbar spinal
cord. Figure 2 shows co-labelling of large neurons in the
ventral cord immunoreactive with both anti-PGRN and
the neurofilament marker SMI32, which strongly labels
motor neurons [64]. SM132 positive signals were found
to predominantly coincide with PGRN immunoreactivity.
The expression of PGRN protein was also prominent in
motor neurons labelled with SMI-32 in primary motor
neurons from spinal cord-DRG cultures (Figure 3a) and
PGRN is expressed by neurons of both central and peripheral nervous systems, in vivo and in vitro in the mouse Figure 1
PGRN is expressed by neurons of both central and peripheral nervous systems, in vivo and in vitro in the 
mouse. Gene expression pattern of murine PGRN in brain (B, C); cervical spinal cord (A, D, E) and primary cultures of disso-
ciated spinal cord-DRG (F, G). In situ hybridization, to detect PGRN mRNA in saggital section of pontine grey matter (A) and 
cross-section of cervical spinal cord (D, E). The majority of neurons throughout the grey matter of the spinal cord express 
PGRN as well as ependymal cells and possibly microglial cells (A). Note in particular the robust expression of PGRN mRNA in 
large motor neurons in panels B, D. Panels C and E illustrate the hybridization signal observed with the sense control applied 
to serial sections to those shown in panels B and D, respectively. (F) Motor neurons (asterisk) as well as other neuronal sub-
types in dissociated spinal cord-DRG cultures, express PGRN; (G) equivalent sense control. Scale bar (panels B-G) represents 
20 μm. Original magnification of panel A was 10×
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was also present in CD11b positive microglia in these cul-
tures (Figure 3c). PGRN did not co-express with an astro-
cyte marker (glial fibrillary acidic protein, GFAP) (Figure
3b). This was not unexpected since these cells are of differ-
ent lineages. Microglia are derived from hematopoietic
stem cells, while astrocytes have oligodendrocyte precur-
sor cells.
Subcellular localization of PGRN within primary spinal 
cord motor neurons and NSC-34 immortalized motor 
neuron cells
Confocal immunofluorescence microscopy was used to
investigate the subcellular distribution of PGRN within
primary motor neurons. Specificity of the immunoreactiv-
ity was validated by antigen competition using murine
PGRN (Figure 4A). PGRN is primarily found in the cell
body with a punctate distribution within the cytoplasm.
However, PGRN expression was also prominent within
the axons of neurons. PGRN was not observed within the
nucleus as defined by TDP43 immunofluorescence, nor
was it present within mitochondria using Cytochrome C
immunofluorescence as the mitochondrial marker (Figure
4B-a,b). Interestingly, PGRN immunostaining did not
colocalize with calreticulin, a calcium-binding chaperone
that facilitates transit of correctly folded proteins and is a
marker for the endoplasmic reticulum (ER) (Figure 5a).
PGRN expression was also apparently absent from the
trans-Golgi network (TGN) as indicated by the marker
GM130 (Figure 5b). This finding was surprising, since the
biosynthetic precursor to PGRN carries a signal peptide,
the structural cue for passage through the secretory path-
way. PGRN did not colocalize with another secreted pro-
tein, chromogranin A, (Figure 5c); however, the size of
PGRN vesicles appeared to be of a similar dimension to
PGRN is localized within motor neurons of the mouse lumbar spinal cord Figure 2
PGRN is localized within motor neurons of the mouse lumbar spinal cord. PGRN is localized within motor neurons 
of the mouse spinal cord. Labelling of paraffin-fixed cross-sections of murine spinal cord with SMI32 marker against hypo-phos-
phorylated neurofilaments (left panel), which is a marker for motor neurons, and anti-PGRN (middle panel). Merged channels 
are shown in the right panel. (a) at original magnification (40×), (b) at magnification (63×).
SMI32 PGRN MERGED
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that of the chromogranin A-containing vesicles. PGRN did
appear to have limited colocalization with synaptophysin
(Figure 6c), which is a protein of the synaptic vesicle exo-
cytosis pathway although at the resolution available we
cannot exclude the possibility that this is due to a non-
specific overlay effect. Few lysosomes, if any were positive
for PGRN (Figure 6a). Antibody to PGRN did not colocal-
ize with SNAP-25, a marker for neurotransmitter vesicle
docking and release sites (Figure 6b).
PGRN expression within the dissociated spinal cord-DRG cultures Figure 3
PGRN expression within the dissociated spinal cord-DRG cultures. Confocal Images taken of dissociated spinal cord 
cultures. PGRN (red) is very clearly expressed within motor neurons (a), labelled with SMI32 (green). PGRN is also expressed 
by microglia, as demonstrated by colocalization between PGRN and CD11b (c). Astrocytes, however, do not express PGRN, 
as demonstrated in (b).BMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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PGRN within motor neurons in primary cultures does not colocalize with the nucleus or mitochondria Figure 4
PGRN within motor neurons in primary cultures does not colocalize with the nucleus or mitochondria. (A) 
Motor neuron labeled with antibody to mouse PGRN (left hand image) is attenuated by antigen-competition with 300 ng 
recombinant mouse PGRN (middle and right hand images). When anti-PRGN was pre-absorbed with 400 ng of mouse recom-
binant PGRN, no signal was observed in the primary motor neurons (not shown). Shown are confocal images taken at 100×. 
(B) PGRN is not distributed in nuclei or mitochondria, organelles that are not part of the secretory pathway. Immunolabelling 
of motor neurons in dissociated spinal cord-DRG cultures with anti-TDP-43 (a) and anti-cytochrome C (b) and anti-PGRN 
(middle column). Merged images (right column) show no colocalization of TDP-43 or cytochrome C with endogenous mouse 
PGRN. Confocal images were captured at 63× magnification, hatched boxes represent 3-5× zoom.BMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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Subcellular localization of PGRN-Enhanced Green 
Fluorescent Protein in NSC 34 cells
Further studies confirmed that the subcellular distribution
of PGRN in NSC-34 cells was comparable to that of the
primary motor neurons (data not shown), including the
labelling of NSC-34 cells with SMI-32 which is consistent
with motor neuron-like properties. Given the disparity
between the apparent absence of PGRN immunoreactivity
in the ER and Golgi apparatus (Figure 5) but the presence
in PGRN of the structural hallmarks for a protein that
should enter the ER and Golgi apparatus including a sig-
nal peptide, glycosylation and disulfide bridging it was
Subcellular localization of PGRN within motor neurons in primary cultures relative to markers for the ER, Golgi apparatus and  chromogranin-A containing vesicles Figure 5
Subcellular localization of PGRN within motor neurons in primary cultures relative to markers for the ER, 
Golgi apparatus and chromogranin-A containing vesicles. Immunolabelling of motor neurons in dissociated spinal 
cord-DRG cultures with anti-Calreticulin (a), anti-GM130 (b), Chromogranin A (c) and anti-PGRN (middle column). Confocal 
images were captured at 63× magnification, hatched boxes represent 3-5× zoom.BMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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essential to re-evaluate the localization of PGRN using an
independent technique. Lacking an extensive selection of
commercial anti-PGRN antibodies validated for use in
immuno-staining available at the time, we developed a
green fluorescent protein (GFP)-tagged PGRN construct to
investigate PGRN subcellular localization further. This
construct, consisting of an enhanced GFP (eGFP) tag
fused to the carboxyl-terminus of the human PGRN gene
(named pEGFP-N1-hPGRN), was transiently transfected
into NSC-34 cells (Figure 7). 48 hours after transfection,
Subcellular localization of PGRN within motor neurons in primary cultures relative to a marker for the lysosomal compart- ment markers for neurotransmitter vesicle trafficking and release (SNAP-25 and synaptophysin) Figure 6
Subcellular localization of PGRN within motor neurons in primary cultures relative to a marker for the lyso-
somal compartment markers for neurotransmitter vesicle trafficking and release (SNAP-25 and synapto-
physin). Immunolabelling of motor neurons in dissociated spinal cord-DRG cultures with LysoTracker™ (a), SNAP-25 (b), 
Synaptophysin (c), and anti-PGRN (middle column). Confocal images were captured at 63× magnification, hatched boxes rep-
resent 3-5× zoom.BMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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confocal microscopy of the cells demonstrated successful
transfection, and a granule-like appearance for the Green
Fluorescent Protein signal that was very different from
that of control empty eGFP vector-transfected cells in
which eGFP vector expression was more nuclear (Figure
8c). The pEGFP-N1-hPGRN expressing cells demonstrated
clear colocalization of EGFP-PGRN within the TGN (Fig-
ure 8a). Furthermore, PGRN distribution was distinct
from that of the mitochondria (Figure 8b). The presence
of the eGFP-tagged PGRN in the Golgi apparatus is not
secondary to PGRN over-expression since when we over-
expressed untagged PGRN in NSC34 cells, as with the pri-
mary motor neurons (Figure 5), no untagged-PGRN
immunoreactivity was detected in the Golgi apparatus
(data not shown).
Over-expression of PGRN in NSC-34 cells promotes a 
neuron-like morphology
The cell line NSC-34 was established by fusing embryonic
spinal cord cells with neuroblastoma cells and in the dif-
ferentiated state are reported to exhibit motor neuronal
properties [65,66]. They are frequently used to investigate
neuroprotective processes and to model motor neuron
degeneration in vitro [51,67-72]. In culture most NSC-34
cells exhibit a rounded and undifferentiated morphology;
however, serum-deprivation stimulates many of the cells
to undergo differentiation and to extend neurite-like pro-
jections [66,73]. Serum-deprivation is also associated
with significant apoptosis of the non-differentiated cells
[73]. NSC-34 cells that express human PGRN were estab-
lished by transfection and selected for stable incorpora-
tion of the human PGRN  gene. Previous work had
demonstrated that human PGRN is mitogenic for murine
cells [28]. Untransfected NSC-34 cells, NSC-34 transfected
with empty PCDNA3 vector (NSC-34/vector), and NSC-
34 cells that were transfected with human PGRN cDNA
subcloned into pcDNA3 (NSC-34/PGRN) continued to
express equivalent levels of murine PGRN mRNA, while
only the NSC-34/PGRN cells express the human PGRN
mRNA (Figure 9A). Over-expression of PGRN protein was
confirmed by Western blot analysis (Figure 9B). In NSC-
34/PGRN cells, PGRN punctate immunoreactivity was
found throughout the cell body and within the projec-
tions (Figure 10). Over-expression of PGRN was associ-
ated with morphological changes, such as flattening of
cell shape and more pronounced neurite-like extensions
(Figure 10).
PGRN over-expression promotes cell survival
To investigate the longevity of NSC-34/PGRN cells, 2
independent cultures were propagated for 2 months in the
absence of serum. Within 20 days no NSC-34/vector cells
survived (not shown), however many NSC-34/PGRN cells
remained alive, retaining a mixed morphology of undif-
ferentiated cells and cells with complex neurite-like pro-
jections [Figure 11A, B, C]. Cells with neuron-like
morphology remained viable at least for 2 months in the
absence of serum [Figure 11C, D]. At day 20, when com-
pared over short intervals (3 hrs) the neuron-like NSC-34/
PGRN cells were changing morphologically, continuing
to elaborate and elongate neuritic processes [Figure 11A].
Between 12 and 15 days following the removal of serum,
cell number significantly decreased in NSC-34/vector cul-
tures, while cultures of NSC-34/PGRN cells showed no
such change (Figure 12A). The absence of extensive prolif-
eration in NSC34-PGRN cells cultured in serum free
medium was further confirmed using a BrdU incorpora-
tion assay. No significant difference in BrdU incorpora-
tion between the NSC-34/vector and NSC-34/PGRN cells
was observed on days 3 and 5. (Figure 12B). There was,
however, a significant increase in TUNEL-positive (i.e.
apoptosing) cells in the NSC-34/vector cultures versus the
NSC-34/PGRN cultures (Figure 12C). The addition of
pEGFP-N1-hPGRN cloning construct Figure 7
pEGFP-N1-hPGRN cloning construct. The human PGRN cDNA (hpgrn) was cloned into the pEGFP-N1 plasmid using 
EcoR1 and Sal1 restriction enzyme digestion sites. The eGFP molecule is fused to the C-terminus of the PGRN protein, and 
therefore does not affect its N-terminal signal sequence that is required for entry into the endoplasmic reticulum. Individual 12 
cysteine granulin modules are designated 1 through to 7 and A through to G. P is paragranulin, a half-granulin module bearing 
six cysteine residues.BMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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exogenous recombinant human PGRN to the medium
also resulted in an enhanced cell survival that became evi-
dent at day 3 of the incubation (Figure 12D).
The stable expression of an shPGRN construct reduced
PGRN mRNA levels by approximately 50% (Figure 13A,
B). Consistent with the qRT-PCR data, significant
decreases in the level of PGRN protein was observed in the
shRNA expressing cells as confirmed by Western blot anal-
ysis (Figure 13C). When the shPGRN cells were cultured
in serum-containing medium, cell proliferation was sig-
nificantly reduced relative to the vector control cells (Fig-
ure 14A) but there was no statistical change in the
proportion of apoptotic cells (Figure 14B). The reduced
proliferation of shPGRN was reversed by the addition of
Transfection of pEGFP-N1-hPGRN plasmid shows granular morphology and particular PGRN localization in Golgi Figure 8
Transfection of pEGFP-N1-hPGRN plasmid shows granular morphology and particular PGRN localization in 
Golgi. The overlap seen with PGRN and the Golgi marker GM130 (a) is very prominent, while there is no overlap between 
mitochondria (b) and PGRN. Panel (c) reveals the pEGFP-N1 vector only transfection, having primarily nuclear GFP signal, and 
a very different subcellular distribution of PGRN, which appears distinctly granular in panels (a and b). Confocal images were 
taken at 63×.
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exogenous human PGRN to the culture medium (Figure
14C).
Discussion
Mutations of the PGRN gene cause frontotemporal lobar
degeneration accompanied by the appearance of ubiquiti-
nated-inclusion bodies [7,8]. The formation of ubiquiti-
nated inclusions occurs in other neurodegenerative
diseases, in particular in ALS [12]. While mutations of
PGRN do not appear to cause ALS [53,54], recent work
suggests that PGRN is neurotrophic for spinal cord motor
neurons [25]. Here we confirmed that PGRN mRNA and
protein is expressed in mouse spinal motor neurons, both
in situ and in primary culture (Figures 1, 2, 3). Other spi-
nal cord neurons, and spinal cord microglia also express
PGRN. The expression in microglia (Figure 3), which also
has been seen in the brains of Alzheimer's patients [8], is
of interest, given that microgliosis accompanies motor
neuron degeneration. Recent evidence demonstrates that
in peripheral inflammation, PGRN inhibits the activity of
the pro-inflammatory cytokine tumor necrosis factor-
alpha [41,43], and it is possible that PGRN may also reg-
ulate inflammatory processes in the spinal cord.
Cells of different origins handle PGRN in different ways.
Whereas epithelial cells appear to secrete PGRN constitu-
tively, innate immune cells including neutrophils process
this growth factor to yield 6 kDa granulin peptides that are
stored within granules [74]. Similarly, PGRN is stored
within the acrosomes of guinea pig spermatozoa [4],
which are vesicular storage structures. In addition, yeast-
two hybrid studies have identified PGRN as a potential
partner for nuclear proteins such as cyclin-T [75], adding
a further level of complexity to the localization and roles
of PGRN.
The subcellular localization and fate of PGRN in neurons
has not been previously defined. PGRN appears to be a
strong candidate for entry into the ER/Golgi pathways
since the PGRN gene encodes a signal sequence for co-
translational entry into the ER, it is rich in disulfide
bridges and N-glycosylation sites both of which form dur-
ing transit through the ER and Golgi compartments. How-
Validation of Stable Transfectants Figure 9
Validation of Stable Transfectants. The motor neuron-neuroblastoma hybrid cell line, NSC-34, was transfected with 
empty pcDNA vector or pcDNA-hPGRN and selected for drug resistance over a three-week period. (A) Species-specific 
PGRN primers were used to confirm the stable integration of hPGRN. (B) Western Blot analysis confirmed presence of 
hPGRN in stable transfectants and not in the vector only control cells.
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ever, it has been suggested that in nerve cells PGRN may
localize with either mitochondria or endosomal-lyso-
somal-like structures [19], which, if correct has profound
implications with respect to the mechanism of action of
PGRN. It was therefore important to clarify the sub-cellu-
lar compartmentalization of PGRN in nerve cells.
Punctate PGRN immunofluorescence was observed
within the cell bodies and in the axons of primary motor
neurons in culture, but not in their nuclei (Figures 4, 5, 6).
We were unable to detect any co-localization of PGRN
with mitochondria in primary motor neurons in culture
(Figure 4B, b). However, we were also unable to detect
immunoreactive PGRN in the ER or Golgi apparatus (Fig-
ure 5a, b). The absence of PGRN immunoreactivity in the
ER/Golgi system despite the structural arguments that sug-
gests it would be likely to enter the secretory pathway,
may reflect a genuine dissociation of localization. Given
the structural features of mature PGRN this may also be a
misleading result due, for example, to low PGRN concen-
trations in the ER/Golgi resulting from rapid transfer
through the secretory pathway. Alternatively the PGRN
antibody may not react with immature protein as it tran-
sits through the ER/Golgi processing pathways. The mon-
oclonal antibody was raised against recombinant mouse
PGRN. It is not known whether it would detect an imma-
ture form of the protein, namely the conformation of
PGRN found in the ER/Golgi compartment before N-gly-
cosylation and formation of disulfide bridges have been
completed. To avoid some of these possible confounding
issues we employed an alternate strategy that was inde-
pendent of immunolocalization to examine the localiza-
tion of PGRN within neuronal cells. NSC-34 motor
neuron-like cells were transfected with a PGRN-eGFP
fusion protein (Figures 7, 8) or with an eGFP control
alone. The eGFP control exhibited green immunofluores-
cence that concentrated mostly in the nucleus. In contrast
PGRN-eGFP exhibited a punctuate fluorescence in the cell
body and axons, but not the nucleus, in a pattern that was
also observed for intrinsic PGRN. The PGRN-eGFP fusion
protein co-localized with GM130, a marker for the trans-
Golgi apparatus, but not with a mitochondrial marker
(Figure 8). We conclude, therefore that neuronal PGRN
enters the ER/Golgi secretory pathway.
PGRN over-expression in NSC-34 cells promotes a neuronal morphology Figure 10
PGRN over-expression in NSC-34 cells promotes a neuronal morphology. Untransfected NSC-34 cells (A-D), trans-
fected with pcDNA3 vector only (E-H) or transfected with pcDNA3-hPGRN (I-L). Micrographs showing the distribution of 
DAPI (A, E, I), F-actin (B, F, J), hPGRN (C, G, K) and merged images (D, H, L). PGRN over-expression promotes more exten-
sive cytoskeletal extensions (hatched box) and is localized within presumptive secretory granules (arrowheads).BMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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There are three major exit pathways from the Golgi appa-
ratus; namely, to the lysosome, to the regulated secretory
pathway, which is characterized by dense core secretory
granules often containing neuropeptides, or to the consti-
tutive secretory pathway. We detected only limited colo-
calization of PGRN with lysosomes (Figure 6a),
suggesting that this is at most only a minor destination for
PGRN. The vesicle-like PGRN structures in the motor neu-
rons did not colocalize with chromogranin A (Figure 5c),
indicating that PGRN does not enter the regulated secre-
tory pathway. There was, however, evidence of some co-
localization between PGRN and synaptophysin (Figure
6c), although further investigation using higher resolu-
tion techniques are necessary to confirm this. PGRN is
unlikely to be secreted primarily from synaptic junctions
since it did not co-localize with the SNAP-25 marker for
neurotransmitter vesicle docking and release sites (Figure
6b). The use of the NSC-34 PGRN-eGFP system in con-
junction with confocal microscopy of primary motor neu-
ron cultures may be useful in defining some aspects of
PGRN secretion by neurons.
We used the NSC-34 cell line to investigate the effects of
PGRN upon cell growth and survival. Using species-spe-
cific reverse-transcription PCR, the expression of human
PGRN was confirmed in the NSC-34/PGRN cells, and
there was no compensatory alteration in the expression of
the murine PGRN mRNA (Figure 9A). PGRN elicited a
change in the appearance of the NSC-34 cells, causing a
more flattened cell shape and more prominent neuritic
PGRN is a sufficient trophic stimulus to maintain prolonged survival of NSC-34 cells in serum-free medium Figure 11
PGRN is a sufficient trophic stimulus to maintain prolonged survival of NSC-34 cells in serum-free medium. 
NSC-34 cells stably transfected with pcDNA3/PGRN and grown in serum-free medium (A) for 20 days in six well plates, the 
cut-out box illustrating the same cells photographed 3 hr later showing continued active extension and retraction of processes; 
(B) for 51 days, and (C, D) for 67 days in serum free medium. All NSC-34/vector control cells died before day 20 (not 
shown). Images were taken at an original magnification of 15×.BMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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extensions (Figures 10, 11). Serum deprivation was
employed as an apoptotic challenge. Upon more pro-
longed incubation in serum-free medium the number of
NSC-34/vector cells declined, becoming statistically sig-
nificantly different from NSC-34/PGRN between days 12
and 15 (Figure 12A). This was due to reduction in apop-
tosis in NSC-34/PGRN cells since the number of TUNEL-
positive cells was significantly lower in cultures of NSC-
34/PGRN cells compared to cultures of NSC-34/vector
cells (Figure 12C). The overall cell number did not signif-
icantly increase in NSC34 cell deprived of serum and,
except at the earliest time points, the percentage of BrdU
positive cells was not significantly changed (Figure 12B),
suggesting that PGRN is cytoprotective rather than prolif-
erative for NSC-34 cells in the absence of serum. The abil-
ity of exogenous PGRN to increase the survival of NSC-34
cells was confirmed by incubating the wild type NSC-34
cells with purified PGRN in serum free medium (Figure
PGRN over-expression prevents apoptosis of NSC-34 cells induced by serum deprivation and exogenous PGRN increases cell  survival Figure 12
PGRN over-expression prevents apoptosis of NSC-34 cells induced by serum deprivation and exogenous 
PGRN increases cell survival. Stable vector only transfectants (pcDNA, open bars) and cells stably over-expressing 
hPGRNs (pcDNA-hPGRN; black bars) were cultured in serum-free RPMI medium in six well plates. (A) Number of cells per 
well were determined at three-day intervals for fifteen days. NSC-34 cells that over-expressed hPGRN demonstrated 
increased survival as compared to controls (N = 2 6 fields 10× magnification/each condition, Asterisks denote P < 0.005). (B) 
Cell proliferation assay based on 18 hr BrdU incorporation following 1, 3 and 5 days culture in serum-free medium in 96 well 
plates. Over-expression of hPGRN during serum deprivation did not significantly increase cell proliferation rates (10 replicates 
per measurement P > 0.1). (C) Apoptosis assay based on the TUNEL- labelling method following 6 days in serum-free medium. 
Over-expression of hPGRN during serum deprivation protected against apoptosis (N = 2 6 fields 10× magnification per condi-
tion. Asterisks denote P < 0.0001). (D) Addition of exogenous PGRN also dramatically increased NSC-34 survival (P < 
0.0001).
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12D). In other non-neuronal cells, such as dermal fibrob-
lasts, PGRN is strongly protective against acidosis [76],
suggesting that it may play a widespread role in protecting
cells against metabolic shocks in their microenvironment.
In order to assess the effect of reduced endogenous PGRN
expression upon proliferation, NSC-34 cells were stably
transfected with shRNA for PGRN and validated in terms
of RNA and protein expression (Figure 13A, B, C). In the
presence of 10% serum, the NSC-34 cells actively prolifer-
ate. Under these conditions the reduction of PGRN mRNA
expression using shRNA silencing decreased cell prolifera-
tion by about 50% (Figure 14A), but had no significant
effect on apoptosis (Figure 14C). PGRN added back to the
culture medium prevented the inhibition of proliferation
brought about by PGRN shRNA (Figure 14B). This con-
firms the specificity of PGRN shRNA and suggests that
PGRN acts primarily through an extracellular mechanism.
Therefore, PGRN supports both cell survival (Figure 12)
and proliferation of NCS-34 cells (Figure 14) and these
activities can be functionally separated depending on
growth conditions.
Short hairpin RNA silencing of PGRN in NSC 34 Figure 13
Short hairpin RNA silencing of PGRN in NSC 34. (A) RT-PCR of PGRN and actin in NSC34 cells stably -transfected 
with shRNA. (B) Relative expression ratio of quantitative RT-PCR showing the expression of PGRN mRNA in NSC34/pRS 
plasmid and NSC34/shPGRN. (C) Western blot analysis of PGRN and actin in NSC34 cells with stably-transfected with 
shRNA.
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PGRN knockdown reduces cell proliferation and exogenous PGRN rescues cell proliferation Figure 14
PGRN knockdown reduces cell proliferation and exogenous PGRN rescues cell proliferation. (A) AlamarBlue cell 
proliferation assay allowing the quantitative measurement of cell proliferation from day 0 to day7 in the presence of serum in 
96 well plates. PGRN knockdown significantly reduced the cell proliferation rate from day 2-3 to day 7-8 (10 replicates per 
determination, p > 0.001). (B) Addition of exogenous PGRN rescued NSC-34 cell proliferation from day 2-3 to 4-5 (repre-
sentative experiment, 10 replicated per determination, P < 0.05). (C) Apoptosis assay based on TUNEL labelling method fol-
lowing 3 days in the presence of serum. PGRN silencing had no significant effect on apoptosis (N = 2, 6 fields 10× magnification 
per determination).
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The enhanced synthesis of PGRN provided prolonged
trophic support for NSC-34 cells in the absence of serum
for periods of at least 60 days (Figure 11D). The extended
serum-free cultures continued to show a mixed popula-
tion of rounded and more-differentiated cells, however
neuron-like cells were maintained throughout. In these
cultures the projections became highly elongated, and
were dynamic structures that displayed structural rear-
rangement over a period of a few hours (Figure 11A).
PGRN may promote neurite extension in cortical neurons
[25], and in short-term NSC34-PGRN cultures (Figure
10), however we cannot exclude the possibility that the
extended length of projections in the long-term serum-
deprived NSC-34/PGRN cultures may be due to improved
overall cellular health rather than the direct stimulation of
neurite outgrowth.
Conclusion
Primary motor neuron cultures and the NSC-34 cell line
provide useful models in which to investigate the cell
biology, function and mode of action of PGRN in neu-
rons. We have demonstrated that PGRN is highly
expressed in normal spinal cord neurons, and that it
enters the ER/Golgi secretory pathway. Over-expression of
PGRN in NSC-34 cells was able to substitute for serum as
a trophic support for periods of up to 2 months. Purified
PGRN added to the medium of serum-deprived NSC34
cells also decreased the rate of cell death. PGRN knock-
down inhibited NSC34 cell proliferation in the presence
of serum. This work supports the hypothesis that PGRN is
neurotrophic and its actions are mediated by extracellular
mechanisms.
Methods
In situ hybridization
ISH was conducted as described by [20] with slight mod-
ification. Paraffin sections were briefly de-paraffinized
and rehydrated in a graded series of ethanol. Tissues were
post-fixed in 4% paraformaldehyde (PFA) (pH7.4) and
washed in 0.5× SSC buffer. Tissues were then permeabi-
lized by incubation with proteinase K (3.5 μg/ml), post-
fixed a second time with 4% PFA and then washed thor-
oughly in PBS and 0.5× SSC. Subsequently, the tissues
were pre-hybridized for 3 hr and then hybridized with 1
ng/μl human-specific Dig-UTP-labelled 238 bp PGRN
sense or antisense RNA probes in hybridization solution
for ~18 h at 42°C. After washing, tissues were incubated
with conjugated Dig antibody and reaction products were
visualized with a brightfield Leica AS LMD microscope.
Preparation of mouse spinal cord for Immunolabelling
Spinal cords were obtained from pregnant CD1 mice. Spi-
nal cords were collected and fixed in 4% paraformalde-
hyde in PBS for 1 hour, cut into cervical, thoracic, lumbar
and sacral sections, and then all were fixed overnight at
the neuropathology department of the Montreal Neuro-
logical Institute. Each section was subsequently processed
for paraffin sectioning. 4 μm slices were cut in the coronal
plane and mounted onto positively charged slides (Fisher
Scientific). Sections were dried in the oven overnight. then
deparaffinized and rehydrated the next day (2 minute
incubation in Citrisolv, 2 minute incubation in Citrisolv,
2 minute incubation in 100% ethanol, 2 minute incuba-
tion in 95% ethanol, 2 minute incubation in 75% etha-
nol, 2 minute incubation in 50% ethanol, rinsed in large
volumes of water, washed in large volume PBS). Antigen
retrieval was performed using a high pH buffer (Tris-
EDTA with 0.05% Tween, pH 9.0), placed in a pressure
cooker for 10 minutes. After cooling, the sections were
placed in a 3% hydrogen peroxide solution to block
endogenous peroxidase activity for 10 minutes. Sections
were rinsed thoroughly in PBS and placed in blocking
buffer (10% (w/v) horse serum, 5% bovine serum albu-
min (BSA), 0.3% Triton-X in PBS) for 1 hour. Sections
were then processed according to the immunohistochem-
istry protocol outlined below.
Primary spinal cord-DRG cultures
Dissociated primary motor neurons cultures were taken
from embryonic day 13 (E13) mice, plated on either 25
mm or 14 mm coverslips (Electron Microscopy Sciences),
and grown for 4 to 7 weeks after dissociation [64]. Cul-
tures were fixed within the original plates using 4% PFA
for 10 minutes, and incubated with permeabilization
buffer (PBST with 0.2% Triton X-100) for 2 minutes, the
cultures were post-fixed for 1 minute with 4%PFA, fol-
lowed by incubation in blocking buffer (PBS with 5% (w/
v) horse serum (Hyclone)) for one hour. Sections were
then processed according to the immunohistochemistry
protocol outlines below.
Immunohistochemistry
All antibodies (primary and their corresponding second-
ary) used for immunohistochemistry are outlined in Table
1. After being incubated in appropriate blocking solution
for the above mentioned periods of time, tissue sections
and/or coverslips were then transferred to fresh blocking
buffer containing the primary antibodies. Incubation with
the primary antibody continued overnight at 4°C. Cul-
tures were washed three times in PBS, and then incubated
with the appropriate secondary antibodies in fresh block-
ing buffer for 45 minutes at room temperature. Cells were
washed three times in PBS. Some cells were additionally
counterstained using 300 nM DAPI in PBS for 5 minutes
at room temperature in the dark. Cultures were washed
three times with PBST, once with ddH2O, and then
mounted onto slides using Immu-mount (Thermo
Fisher), or fluorescent mounting medium (Dako). Fluo-
rescence was visualized by confocal microscopy (LSM
510), using argon and HeNe1 lasers. Images were proc-BMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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essed with Zen software. Identification of primary motor
neurons within the heterogeneous culture was based
upon SMI32 immunoreactivity and cell body size [64].
To control for nonspecific binding of the mouse PGRN
antibody, antigen-competition was carried out by pread-
sorbing the antibody at 1:500 dilution with 300 ng/mL
and 400 ng/mL recombinant mouse PGRN (Alexis Bio-
chemicals). The mixture was incubated for 24 hr at 4°C
and following centrifugation, the supernatant was col-
lected and used as a primary antibody, as described above.
Cloning and Transfection of pEGFP-N1-hPGRN vector
PCR primers were designed to include digestion sites for
restriction enzymes. For pEGFP-N1-hPGRN, forward
primer 5' C GAA TTC GAA TTC ACC ATG TGG ACC CTG
GTG AGC 3' and reverse primer 5' GAC GTC GAC CCC
AGC TGT CTC 3' were designed for EcoR1 and Sal1 diges-
tion respectively. PCR was carried out under the following
conditions: 94°C for 10 minutes, then 40 cycles of 94°C
1 min, 62°C 1 min, 72°C 1 min, followed by 10 minutes
at 72°C. When cycle was finished, PCR block was kept at
4°C until samples were run on 1% agarose electrophore-
sis gel.
1 ug pEGFP-N1 plasmid and 1 ug single stranded hpgrn
DNA was used in the restriction digest with EcoR1 and
Sal1. Ligation mixtures were created as a 3:1 ratio, vector
size to insert size respectively. 1 μl of T4 DNA Ligase
(BioLabs) was added and tube was incubated at 20°C for
20 minutes. Competent cells (E. Coli, aliquots of 50 μl,
Invitrogen) incubated on ice for 30 minutes, then heat
shocked at 37°C for 2 minutes, followed by chilling on ice
for 5 minutes. 950 μl LB broth (at room temperature) was
added to the cells, which were subsequently incubated at
37°C for 1 hour. Cells were centrifuged at 12000 rpm for
30 seconds. 100 μl of the pellet (plus media) was spread
onto a kanamycin coated LB plated Petri dishes and
grown overnight in a 37°C incubator. Individual colonies
were then amplified and confirmation of successful liga-
tion was achieved through restriction enzyme digestion.
The NSC-34 cell line (generous gift from Dr. Neil Cash-
man) was maintained in DMEM with 10% fetal bovine
serum unless otherwise stated [65]. NSC-34 cells were
grown on 25 mm German glass coverslips in 6 well plates.
At 70% confluency, cells were washed twice in serum-free
OPTIMEM in preparation for transfection. Serum-free,
antibiotic-free OPTIMEM and Lipofectamine were com-
bined according to the manufacturer's instructions. For
each coverslip, 4 ug of pEGFP-N1-hPGRN, or control
empty vector pEGFP-N1, was added to the appropriate
volume of OPTIMEM-lipofectamine solution and mix-
tures were incubated for 30 minutes prior to addition to
well containing 1.5 ml of serum-free DMEM. Cells were
incubated with the transfection mixture for 4 hours, after
which the mixture was replaced with DMEM containing
10% FBS and gentamycin.
NSC-34: Developing Stable Cell Lines
For stable transfections NSC-34 cells were transfected with
human PGRN (pcDNA-PGRN) or empty vector (pcDNA)
using Lipofectamine (Invitrogen) and selected with G418
for one month according to manufacturer's instructions.
RT-PCR for NSC-34/HPGRN cell line
To confirm the over-expression of human PGRN and to
assess the expression of endogenous murine PGRN in
NSC-34 cells, total RNA was isolated using Trizol reagent
(Invitrogen) and 5 μg was used for cDNA synthesis using
AMV reverse transcriptase (Invitrogen) according to man-
ufacturer's instructions. Species-specific primer sets
designed to detect human and mouse PGRN mRNA were
5'-GGACAGTACTGAAGACTCTG-3'/5'-GGAT-
GGCAGCTTGTAATGTG-3' and 5'-GCTACAGACTTAAG-
GAACTC-3'/5'-GAAATGGCAGTTTGATACGG-3',
respectively. Beta-actin mRNA was used as a loading con-
trol employing 5'-GAAGTGTGACGTGGACATCC-3' and
5'-GAAATGGCAGTTTGATACGG-3' primers. Polymerase
Table 1: List of primary and secondary antibodies used for immunocytochemistry
ANTIBODY TITRE SOURCE SECONDARY
PGRN 1:500 R&D SYSTEMS DONKEY-ANTI-SHEEP (ALEXA FLUOR 488 or 594
TDP-43 1:100 PROTEINTECH DONKEY-ANTI-RABBIT (ALEXA FLUOR 488)
CYTOCHROME C 1:400 PHARMINGEN DONKEY-ANTI-MOUSE (ALEXA FLUOR 488 OR 594)
CALRETICULIN 1:400 STRESSGEN DONKEY-ANTI-RABBIT (ALEXA FLUOR 488 OR 594)
GM130 1:300 PHARMINGEN DONKEY-ANTI-MOUSE (ALEXA FLUOR 488 OR 594)
CHROMOGRANIN A 1:100 RDI DONKEY-ANTI-RABBIT (ALEXA FLUOR 488)
SNAP-25 1:1000 SIGMA DONKEY-ANTI-RABBIT (ALEXA FLUOR 488)
SYNAPTOPHYSIN 1:200 SIGMA DONKEY-ANTI-RABBIT (ALEXA FLUOR 488)
CD11b 1:100 BIOLEGENDS NONE -(PRIMARY LABELED WITH ALEXA-FLUOR 488)
GFAP 1:400 PROTEINTECH DONKEY-ANTI-RABBIT (ALEXA FLUOR 488)
SMI32 1:1000 STERNBERGER DONKEY-ANTI-MOUSE (ALEXA FLUOR 488)BMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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chain reaction was completed using Platinum Taq (Invit-
rogen) with a denaturation of 2 min at 94°C; 35 cycles at
94°C, 30 sec; 55°C, 30 sec; 72°C, 30 sec; and a final
extension of 5 min at 72°C.
Design and transfection of ShRNA -mPGRN into NSC-34 cells
The 29 nucleotide stretches within the coding region of
murine PGRN cDNA unique in the genome were identi-
fied and an shRNA construct was designed by OriGene
Technologies. NSC34 cells were cultured in DMEM with
10% fetal bovine serum unless otherwise stated [65]. For
stable transfection, cells were seeded onto 6 well plates.
When the cultures were 80% confluent, NSC-34 cells were
transfected with shRNA-m PGRN (pRS/shPGRN) or con-
trol vector (pRS vector alone, Origene Technologies)
using Fugene (Roche) and selected with puromycin (Inv-
itrogen) for six weeks according to manufacturer's instruc-
tions.
RT-PCR for shPGRN cell line
To confirm the knockdown effect of murine PGRN in
NSC-34 cells, total RNA was isolated using Trizol reagent
(Invitrogen) and 5 μg was used for cDNA synthesis using
AMV reverse transcriptase (Invitrogen) according to man-
ufacturer's instructions. Species-specific primer set
designed to detect mouse PGRN mRNA was 5'-GCTACA-
GACTTAAGGAACTC-3'/5'-GAAATGGCAGTTTGA-
TACGG-3'. Beta-actin mRNA was used as a loading
control employing 5'-GAAGTGTGACGTGGACATCC-3'
and 5'-GAAATGGCAGTTTGATACGG-3' primers.
Polymerase chain reaction was completed using Taq DNA
polymerase (Invitrogen) with a denaturation of 2 min at
94°C; 35 cycles at 94°C, 30 sec; 55°C, 30 sec; 72°C, 30
sec; and a final extension of 5 min at 72°C.
Quantitative Real Time PCR (QRT-PCR)
QRT-PCR was performed as described elsewhere [41]
using a Light Cycler FastStart DNA Master SYBR Green I kit
(Roche). Melting curve analysis confirmed the presence of
a single product for every PCR primer used, and genomic
contamination was excluded by amplification of a control
sample without reverse transcription. Quantitation was
calculated using the formula:
where RER is relative expression ratio, E is the efficiency of
the PCR reaction, ΔCP is the difference in crossing points
and ref is the corresponding value for a reference gene
(Actin) [77]. PCR primers (as described for conventional
RT-PCR) were synthesized by Invitrogen. Each RT-PCR
experiment was performed using 3 independent RNA
extracts in duplicate.
Western blot analysis
NSC34 cells were lysed and proteins were solubilized in
RIPA buffer (Sigma) containing Complete Protease Inhib-
itor Cocktail (Roche Applied Science). Lysates were incu-
bated on ice for 5 min, briefly sonicated and centrifuged
at 13,000 rpm for 15 min at 4°C. Supernatants were
mixed with equal amount of in 2× sample buffer boiled
for 5 min, and resolved on a 10% SDS-PAGE gel. Proteins
were transferred onto a nitrocellulose membrane and
blocked over-night with membrane blocking agent (GE
Healthcare) at 4°C. The blots were incubated in PBST
with 1:250 anti-human PGRN polyclonal antibody (rab-
bit anti-human PGRN generated in our laboratory) for 1
hour followed by extensive washing. After incubating with
an anti-rabbit or -mouse IgG-horseradish peroxidase
(HRP)-conjugated secondary antibody (diluted 1:4,000)
at room temperature for 1 hour and blots were visualized
using enhanced chemiluminescence (GE Healthcare)
according to the manufacturer's instructions. The same
blot was stained with mouse monoclonal β-actin anti-
body (AC-40; Sigma) at a dilution of 1:1000 as a control
for total protein loading.
Survival Assays
Serum deprivation assays were carried out in 6-well plates
using 200,000 cells/well and cultured in 4 ml of RPMI
(with glutamine) for 3, 6, 9, 12 and 15 days without the
addition or exchange of fresh medium. For each time
point the average cell number was determined over 6 vis-
ual fields per well at 10× magnification using an Olympus
phase-contrast microscope. For long term cultures NSC-
34 cells were plated at a density of 200,000/well in 6-well
plates and maintained in serum free RPMI medium. Fresh
serum-free medium was provided every 10 days and 10×
magnification photos taken at intervals for 2 months
using an Olympus phase-contrast microscope.
For stimulation with exogenous PGRN, NSC-34 cells were
plated in 96 well plates at 6000 cells per well. The follow-
ing day the cultures were treated with or without PGRN at
100 ng/ml under serum-free conditions in RPMI for 5
days. The PGRN was prepared by transient transfection in
COS7 cells as previously described, and purified to homo-
geneity by reversed-phase high pressure liquid chroma-
tography [78]. The purity and identity of the protein was
confirmed by SDS-gel electrophoresis followed by silver
staining and Western blotting. Cell viability was assessed
using the AlamarBlue (Biosource, Camarillo, CA) colori-
metric assay. The AlamarBlue assay allows quantitative
analysis of cell viability due to metabolic activity that
results in a chemical reduction of AlamarBlue from the
oxidized (blue) form to the reduced (pink) form. Plates
were read in an ELISA plate reader at 2 different wave-
lengths, 570 nm and 630 nm 24 hrs after addition of
AlamarBlue.
RER of target E E target
CPtarget control sample
ref
CP =
− () / ( )
() ΔΔ    ref  control sample () −BMC Neuroscience 2009, 10:130 http://www.biomedcentral.com/1471-2202/10/130
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Apoptosis TUNEL assay
NSC-34 cells were plated on photo-etched German glass
coverslips (Electron Microscopy sciences) in 6-well plates
at 200,000/well and cultured in 4 ml of RPMI (with
glutamine) for six days. At time of fixation, cells were
washed twice in PBS, and then fixed using 4% PFA/PBS for
20 min. After being rinsed three times in PBST, cells were
incubated in permeabilization buffer (0.2% Triton X-100
in PBST) for 20 min. Cells were subsequently post-fixed
for 10 min with 4% PFA/PBS. After being washed exten-
sively with PBST, they were stored at 4°C in sterile PBS. At
time of processing, cells were rinsed once with PBS, fol-
lowed by overlay with reaction solution from the Fluores-
cein In Situ Death Detection Kit (Roche Applied Science),
as directed by manufacturer's instructions. Cells were
incubated at 37°C for 1 hr, and then rinsed twice with
PBST at room temperature in the dark. After rinsing three
times in PBST, cells were counterstained with 300 nM 4',
6-diamino-2-phenylindole (DAPI) for 5 min in the dark.
Cells were then rinsed twice with PBST, once with ddH2O
and then mounted onto slides using Immu-mount
(Thermo Fisher). Fluorescence was visualized with an
Axioskop2 microscope equipped with appropriate filters
and total cells (DAPI) versus apoptotic cells (FITC) were
counted manually by visual inspection.
Chemiluminescent BrdU proliferation assay
NSC-34 cells were plated in 96-well plates at 6000/well
and cultured in RPMI (with glutamine) for 5 days. Eight-
een hours prior to fixation/processing, BrdU labeling
solution (Roche Applied Sciences) was added to each well
at a concentration of 10 μM. At the time of fixation, the
excess unincorporated BrdU labeling medium was
removed and cells were dried and then fixed using FixDe-
nat solution (Roche Applied Sciences) for 30 min. FixDe-
nat solution was decanted and the cells were incubated
with anti-BrdU-POD (1:100) for 120 min. Cells were
rinsed three times with washing solution for five min
each. Cells were then placed in substrate solution for 3
min at room temperature on a sample shaker. The light
emission from the samples was measured using micro-
plate a luminometer (LMAX II-384, Molecular Devices)
with photomultiplier technology and expressed as relative
light units per second (rlu/s).
AlamarBlue Cell Proliferation Assay
NSC 34 cells were plated in 96 well plates and cultured in
DMEM with 10% fetal bovine serum. For rescue experi-
ments the cells were cultured with or without 200 ng/ml
of human PGRN at day 1. Cell number was assessed using
the AlamarBlue (Biosource, Camarillo, CA) colorimetric
assay from day0 to day7. Plates were read in an ELISA
plate reader at 2 different wavelengths, 570 nm and 630
nm 24 hrs after addition of AlamarBlue. Cell based Stand-
ard curve was prepared using 2000, 6000, 10000, 20000
and 50000 cells per well and corresponding absorbance
values. Cell numbers of unknowns were calculated using
Standard curve.
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